Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -104.81% is in line with its 5-year average of -103.84%, around the middle of its 5-year range (-205.74%–-6.32%).
As of the fiscal period ended Monday, June 30, 2025. 13.25% above its 12-month average of -120.82%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
-104.81%
EBITDA MARGIN AVG TTM
-120.82%
EBITDA MARGIN AVG 3Y
-119.88%
EBITDA MARGIN AVG 5Y
-103.84%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.25%
CURRENT VS 3Y AVG
+12.57%
CURRENT VS 5Y AVG
-0.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
23andMe Holding Co.
Market Cap
$15.31M
EBITDA Margin
-104.81%
TTM Avg
-120.82%
3Y Avg
-119.88%
5Y Avg
-103.84%
Market Cap
$471.59M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$1.22B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$2.64B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$6.19B
EBITDA Margin
6.82%
TTM Avg
6.08%
3Y Avg
-0.44%
5Y Avg
-8.67%
Market Cap
$8.09B
EBITDA Margin
-3.14%
TTM Avg
-1.08%
3Y Avg
-5.02%
5Y Avg
-19.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -104.81% | -120.82% | -119.88% | -103.84% |
| NRC Health (NRC)vs › | $439.69M | 21.99% | 25.40% | 28.98% | 31.97% |
| Shoulder Innovations, Inc. (SI)vs › | $471.59M | -48.80% | -44.09% | -45.35% | -45.35% |
| Teladoc Health, Inc. (TDOC)vs › | $1.22B | 3.96% | -13.21% | -146.19% | -104.68% |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 22.42% | 17.70% | -0.76% | -37.34% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.68B | 16.41% | 1.22% | -1.65% | 4.31% |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.19B | 6.82% | 6.08% | -0.44% | -8.67% |
| Tempus AI, Inc. (TEM)vs › | $7.69B | -11.84% | -53.07% | -52.51% | -64.32% |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | -3.14% | -1.08% | -5.02% | -19.32% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.80B | 18.42% | 17.41% | 19.12% | 20.05% |
Gross Margin
53.3%
EBITDA Margin
-104.8%
Operating Margin
-126.7%
Net Margin
-134.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -104.81% |
| 2025-03-31 | -205.74% |
| 2024-12-31 | -6.32% |
| 2024-09-30 | -123.48% |
| 2024-06-30 | -163.73% |
| 2024-03-31 | -82.75% |
| 2023-12-31 | -164.47% |
| 2023-09-30 | -142.04% |
| 2023-06-30 | -166.19% |
| 2023-03-31 | -65.93% |
| 2022-12-31 | -131.15% |
| 2022-09-30 | -77.49% |
| 2022-06-30 | -124.29% |
| 2022-03-31 | -60.05% |
| 2021-12-31 | -156.66% |
| 2021-09-30 | -75.32% |
| 2021-06-30 | -62.31% |
| 2021-03-31 | -70.40% |
| 2020-12-31 | -72.66% |
| 2020-09-30 | -60.01% |
| 2020-06-30 | -64.90% |
